Astrazeneca Share News (AZN)

UPDATE: BROKER RATINGS SUMMARY: Buy Wolseley, Sell Berkeley - Goldman

Looking for Brexit-proof portfolios? Try drugs, alcohol and tobacco

By Tricia Wright and Vikram Subhedar LONDON, June 29 (Reuters) - Health, safety and even some traditional 'sin stocks' have already shown signs of weathering Brexit-related storms in European equity markets over the past week. The flight to safety in the aftermath of last week's Brexi

European healthcare first sector to recover Brexit losses

LONDON, June 29 (Reuters) - The rush to large-cap, high quality, dividend-paying pharmaceutical stocks in the aftermath of Brexit has helped Europe's healthcare index erase all its losses since last week's vote. The healthcare index, up 1.4 percent on Wednesday, is the only regional sector

Astrazeneca wins approval for new antibiotic in fight against drug resistance

(ShareCast News) - AstraZeneca has won European regulatory approval for Zavicefta, a combination antibiotic developed in response to the increasingly urgent need for new drugs to treat serious infections that are becoming increasingly resistant to antibiotics. Zavicefta, a combination of ceftazidime

AstraZeneca Gets EU Approval For Zavicefta Antibiotic Treatment

Sunday share tips: EasyJet, Randgold, Imperial Brands, AstraZeneca

(ShareCast News) - Sell EasyJet shares due to the likely turbulence sparked by the Brexit vote, said the Sunday Times' Inside the City column. The budget airline was created by Stelios Haji-Ioannou in the wake of the 1992 European Union Treaty on Open Skies, one of the supposedly rare bits of Brusse

Britain's FTSE closes down 3.2 pct, banks and housebuilders slump

By Sudip Kar-Gupta LONDON, June 24 (Reuters) - Britain's top shares index fell on Friday, led lower by banks and homebuilders, but staged a sharp recovery from its initial slump caused by the country's decision to leave the European Union. The FTSE 100 index initially dived more than

UPDATE 2-From drinks to drugs to cars: Global business hit by EU vote

(Adds further details from companies) By Ben Hirschler and Martinne Geller LONDON, June 24 (Reuters) - Chief executives from Tokyo to Denver prepared for long-term disruption, job cuts and lower profits on Friday after Britain's vote to leave the European Union raised widespread fears

UPDATE 1-From beer to drugs to cars: Global business laments EU vote

By Ben Hirschler and Martinne Geller LONDON, June 24 (Reuters) - Chief executives from Tokyo to Denver woke up on Friday to currency turmoil, plunging share prices and tough decisions after Britain's vote to leave the European Union raised widespread fears over economic growth. In Bri

WINNERS & LOSERS SUMMARY: Gold, Dollar Exposure Rewarded Post-Brexit

UPDATE: UK Chemicals And Pharmaceuticals Must "Look To Future"

From beer to drugs to cars: Global business laments EU vote

By Ben Hirschler and Martinne Geller LONDON, June 24 (Reuters) - Shocked chief executives from Mumbai to Denver woke up on Friday to face tough decisions over how to respond to Britain's vote to leave the European Union. In Britain itself, businesses as diverse as engineering group Ro

UPDATE 3-U.S. spurns AstraZeneca's nasal spray flu vaccine as ineffective

(Adds expert's comments) By Ben Hirschler and Julie Steenhuysen LONDON/CHICAGO, June 23 (Reuters) - U.S. health officials have advised doctors not to use AstraZeneca's FluMist in the upcoming flu season based on three years of U.S. data showing that the nasal spray vaccine is not effe

UPDATE 2- U.S. spurns AstraZeneca's nasal spray flu vaccine as ineffective

(Adds details from CDC, background, byline, dateline) By Ben Hirschler and Julie Steenhuysen LONDON/CHICAGO, June 23 (Reuters) - U.S. health officials have advised doctors not to use AstraZeneca's FluMist in the upcoming flu season based on three years of U.S. data showing that the na

UPDATE 1-AstraZeneca takes $80 mln hit as U.S. spurns nasal flu vaccine

(Adds shares, analyst comment, further details) By Ben Hirschler LONDON, June 23 (Reuters) - AstraZeneca said it would take an $80 million writedown on stocks of its flu vaccine Flumist Quadrivalent, which is sprayed into the nose, after U.S. health authorities decided they would not